The initial differential diagnosis included Graves thyroid eye disease, a neuromuscular junction disorder (myasthenia gravis or botulism), oculopharyngeal muscular dystrophy, Miller Fisher variant of Guillain-Barré syndrome, and progressive muscular dystrophy.
Free thyroxin and thyroid stimulating hormone levels were normal. Thyroid antibodies were negative. Acetylcholine receptor antibody assay was negative and repetitive nerve stimulation to exclude a neuromuscular junction disorder was normal. Electromyography of proximal upper limb muscles revealed an increased number of short duration motor units consistent with borderline myopathy. Nerve conduction velocities were normal, reducing the likelihood of an immunemediated inflammatory neuropathy.
Due to the chronicity of symptoms, presence of gaze paresis, myopathic findings on neurophysiologic assessment, and family history of ocular complications suggestive of dominant inheritance, a muscle biopsy was performed. Polyadenylate bindingprotein nuclear 1 (PABPN1) gene mutation analysis to exclude oculopharyngeal muscular dystrophy was deferred pending muscle biopsy analysis.
The muscle biopsy showed 13% cytochrome c oxidase (COX)-deficient fibers, significant numbers of ragged red fibers but no excess of lipid or glycogen accumulation, and subsarcolemmal accumulation of abnormal mitochondria suggestive of a mitochondrial cytopathy (figure 1A Due to the presence of multiple mtDNA deletions indicative of an mtDNA maintenance defect, polymerase ␥ (POLG1) gene amplification and sequencing was performed. This detected two previously described heterozygous mutations in compound p.T251I and p.P587L, frequently found in cis and subsequently confirmed as showing an autosomal dominant pattern of inheritance.
No mutations were identified in the PEO1 (Twinkle) and SLC25A4 (ANT1) genes.
The patient presented 10 months later with an unpleasant "jumping" sensation in her feet when at rest which was relieved by movement. Symptoms were worse at night and she also described sudden involuntary movements of her lower limbs. These symptoms did not subjectively impact on sleep hygiene. Family history was negative for these symptoms.
Questions for consideration:
1. What condition is this patient describing? 2. What additional tests would you consider at this time?
GO TO SECTION 4 SECTION 4
This patient's symptoms were consistent with restless legs syndrome (RLS) and periodic limb movements of sleep. Medications included ubiquinone only. Initial blood tests including full blood count, iron, ferritin, glucose, renal and liver profiles, thyroid function tests, and vitamin B12 levels were normal. Nerve conduction studies were normal excluding a peripheral neuropathy. Due to the risks associated with developing a dopamine deficient syndrome with POLG mutations, 123-I Ioflupane DatSCAN imaging was performed.
This showed asymmetric uptake of tracer in the putamen with relative reduced uptake in the right putamen compared to the left side (figure 2) consistent with impairment of the dopamine transporter mechanism suggestive of parkinsonism. She declined pharmacologic intervention for symptom control. The results of POLG1 gene analysis in the affected relatives revealed the same heterozygous mutations.
DISCUSSION Mutations of the POLG1 gene are thought to account for up to 25% of adult mitochondrial disease presentations. 1 This patient presented with gaze paresis, multiple mtDNA deletions in skeletal muscle, and a family history of ptosis. It is widely accepted that this constellation of factors warrants consideration of POLG1 as a possible diagnosis. 1 Autosomal dominant progressive external ophthalmoplegia (adPEO) caused by a mutation in POLG1 was first described in 2001.
2 Pathogenic mutations in the genes encoding POLG, the enzyme that synthesizes mitochondrial DNA, have been described in patients with dominant, recessive, and sporadic PEO, as well as in patients presenting with parkinsonism, neuropathy, late onset ataxia, and Alpers syndrome. 3 Mitochondrial dysfunction has been linked to Parkinson disease (PD) with mtDNA deletions and rearrangements found in the substantia nigra of patients with PD and individuals with POLG mutations. 4, 5 RLS is a common yet underdiagnosed condition with multiple causes. 6 Secondary causes excluded in this patient include iron deficiency, pregnancy, and end-stage renal failure. 7 The patient fulfilled the essential criteria for RLS: the urge to move the legs which is initiated or worsened by inactivity, relieved by movement and worse at night. 6, 8 High prevalence of RLS is reported in this patient's age group and gender (women, aged 50 -59 years).
9 Associated features are a family history of RLS, a positive therapeutic response to dopaminergic drugs, periodic limb movements in sleep, and sleep disturbance. 6 Pathophysiologic concepts for RLS include dysfunction of the dopaminergic system based on clinical observation and response to dopamine and dopamine agonists. RLS symptoms may be prevalent in PD; however, an etiologic link has not been shown. Unlike PD, RLS is not a degenerative disorder and there is little evidence of degeneration of dopaminergic neurons, although neuroimaging shows a subtle functional impairment of the dopaminergic system with reduced dopamine binding in the caudate and putamen. 10 Although extrapyramidal features have been described in POLG1 mutations, moreover, an association with RLS has yet to be reported.
The patient we describe has an unusual presentation of a commonly occurring syndrome, RLS, and extends the ever-evolving spectrum of clinical phenotypes attributable to mutation of the POLG1 gene. 
